Commentary

Article

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO

Speakers

  • Suzanne B. Coopey, MD, FACS | Allegheny Health Network
  • Christie J Hilton, DO | Allegheny Health Network
  • Casey A Moffa, DO | Allegheny Health Network
  • Gurleen Pasricha, MD | Meadville Medical Center
  • Sarah M Miller, DO | Allegheny Health Network
  • Emil J Fernando, MD | Allegheny Health Network
  • Colin E Champ, MD | Allegheny Health Network

Topics

  • CDK4/6 Inhibitor Use in Early-Stage ER-Positive, HER2-Negative Breast Cancer
  • CDK4/6 Inhibitor Use in Metastatic ER-Positive, HER2-Negative Breast Cancer
  • ADCs in Breast Cancer
  • Cases From the Community
  • Ipsilateral Breast Tumor Recurrence
  • Case Discussion: Multidisciplinary Management of Ipsilateral Breast Tumor Recurrence
  • Exercise Oncology: Exert Breast Cancer

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Antonio Llombart-Cussac, MD, PhD
Joyce O'Shaughnessy, MD
Adrienne G. Waks, MD,
David Rimm, MD, PhD
This series features 2 KOLs
This series features 2 KOLs
Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06
4 KOLs are featured in this series.
4 KOLs are featured in this series.